Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23885041,flow rate,"The chromatographic separation was achieved within 3.0 min by an isocratic mobile phase consisting of 0.2% formic acid in water-acetonitrile (30:70, v/v), flowing through Agilent Eclipse-plus C18, 100 × 4.6 mm, 3.5 µm analytical column, at a flow rate of 0.6 mL min(-1).",LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23885041/),[ml] / [min],0.6,1941,DB08860,Pitavastatin
,25234550,relative bioavailability,The mean (SD) relative bioavailability calculated from the ratios (T/R) of AUC0-t was 101.3% (19.7%).,"Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),%,101.3,3384,DB08860,Pitavastatin
,25234550,Tmax,"No significant differences were found among Tmax (0.742 ± 0.276, 0.674 ± 0.202, and 0.689 ± 0.226, respectively) for reference tablet 1, reference Supplemental Table II in the online version at 10.1016/j.clinthera.2014.06.21, and test tablet by a Wilcoxon test (P > 0.05).","Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),,0.742,3385,DB08860,Pitavastatin
,25234550,Tmax,"No significant differences were found among Tmax (0.742 ± 0.276, 0.674 ± 0.202, and 0.689 ± 0.226, respectively) for reference tablet 1, reference Supplemental Table II in the online version at 10.1016/j.clinthera.2014.06.21, and test tablet by a Wilcoxon test (P > 0.05).","Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),,0.674,3386,DB08860,Pitavastatin
,25234550,Tmax,"No significant differences were found among Tmax (0.742 ± 0.276, 0.674 ± 0.202, and 0.689 ± 0.226, respectively) for reference tablet 1, reference Supplemental Table II in the online version at 10.1016/j.clinthera.2014.06.21, and test tablet by a Wilcoxon test (P > 0.05).","Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25234550/),,0.689,3387,DB08860,Pitavastatin
,21193152,bioavailability,"The bioavailability of pitavastatin is, at 60%, higher than that of any other statin and the majority of the bioavailable fraction of an oral dose is excreted unchanged in the bile.",Pitavastatin - pharmacological profile from early phase studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21193152/),%,60,4646,DB08860,Pitavastatin
,17460607,area under plasma concentration-time curve from 0 to 24 h (AUC(0-24)),"In SLCO1B1, pitavastatin area under plasma concentration-time curve from 0 to 24 h (AUC(0-24)) for groups 1, 2, and 3 was 81.1+/-18.1, 144+/-32, and 250+/-57 ng h/ml, respectively, with significant differences among all three groups.","SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460607/),[h·ng] / [ml],81.1,20038,DB08860,Pitavastatin
,17460607,area under plasma concentration-time curve from 0 to 24 h (AUC(0-24)),"In SLCO1B1, pitavastatin area under plasma concentration-time curve from 0 to 24 h (AUC(0-24)) for groups 1, 2, and 3 was 81.1+/-18.1, 144+/-32, and 250+/-57 ng h/ml, respectively, with significant differences among all three groups.","SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460607/),[h·ng] / [ml],144,20039,DB08860,Pitavastatin
,17460607,area under plasma concentration-time curve from 0 to 24 h (AUC(0-24)),"In SLCO1B1, pitavastatin area under plasma concentration-time curve from 0 to 24 h (AUC(0-24)) for groups 1, 2, and 3 was 81.1+/-18.1, 144+/-32, and 250+/-57 ng h/ml, respectively, with significant differences among all three groups.","SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460607/),[h·ng] / [ml],250,20040,DB08860,Pitavastatin
,17460607,AUC(0-24),"In contrast to SLCO1B1, AUC(0-24) in groups 1, 4, and 5 was 81.1+/-18.1, 96.7+/-35.4, and 78.2+/-8.2 ng h/ml, respectively.","SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460607/),[h·ng] / [ml],81.1,20041,DB08860,Pitavastatin
,17460607,AUC(0-24),"In contrast to SLCO1B1, AUC(0-24) in groups 1, 4, and 5 was 81.1+/-18.1, 96.7+/-35.4, and 78.2+/-8.2 ng h/ml, respectively.","SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460607/),[h·ng] / [ml],96.7,20042,DB08860,Pitavastatin
,17460607,AUC(0-24),"In contrast to SLCO1B1, AUC(0-24) in groups 1, 4, and 5 was 81.1+/-18.1, 96.7+/-35.4, and 78.2+/-8.2 ng h/ml, respectively.","SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460607/),[h·ng] / [ml],78.2,20043,DB08860,Pitavastatin
,15194707,IC(50),"Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,72,24500,DB08860,Pitavastatin
,15194707,IC(50),"Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,24,24501,DB08860,Pitavastatin
,15194707,IC(50),"They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,28,24502,DB08860,Pitavastatin
,15194707,IC(50),"They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,4,24503,DB08860,Pitavastatin
>,34330719,hepatic extraction ratio,"After the first dose, all statins were rapidly cleared from the circulation (hepatic extraction ratio > 0.7) and excreted into the bile.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,0.7,26059,DB08860,Pitavastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,7.2,26060,DB08860,Pitavastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,3.1,26061,DB08860,Pitavastatin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,2.6,26062,DB08860,Pitavastatin
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[h·ng] / [ml],138,51672,DB08860,Pitavastatin
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],63.8,51673,DB08860,Pitavastatin
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[h·ng] / [ml],106,51674,DB08860,Pitavastatin
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],49.5,51675,DB08860,Pitavastatin
,27121674,Cmax,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],63.8,51676,DB08860,Pitavastatin
,27121674,Cmax,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],49.5,51677,DB08860,Pitavastatin
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,2.0,74942,DB08860,Pitavastatin
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.9,74943,DB08860,Pitavastatin
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.0,74944,DB08860,Pitavastatin
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74945,DB08860,Pitavastatin
,29643253,IC50,Use of in vitro IC50 obtained following 1 hour preincubation with rifampicin (0.54 µM) predicted correctly the change in mean i.v. clearance and oral exposure of statins as a function of mean unbound maximum plasma concentration of rifampicin.,In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74946,DB08860,Pitavastatin
,31915110,flow rate,"Following liquid-liquid extraction of the analytes from plasma, chromatographic separation was accomplished on a Waters Reliant C18 column (4.6 × 250 mm, 5 µm) using ACN-5 mM Sodium acetate buffer (80:20, v/v; pH adjusted to 3.5 with acetic acid) as mobile phase at a flow rate of 0.8 mL/min and wavelength of 234 nm.",Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31915110/),[ml] / [min],0.8,96517,DB08860,Pitavastatin
above,31915110,Extraction recovery,Extraction recovery observed for both analytes was above 90% as well as reproducible and consistent.,Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31915110/),%,90,96518,DB08860,Pitavastatin
,15118259,Vmax /Km,"(14)C-Pitavastatin is metabolized with CYP2C9 to 8-hydroxy derivative, but its Vmax /Km was about 2 micro l/min/mg, about 1/8 to 1/100 in comparison to the reported values of other statins, indicating that pitavastatin is hardly metabolized.",[Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118259/),[μl] / [mg·min],2,99089,DB08860,Pitavastatin
,21882531,m/z,"Plasma samples were determined with LC-MS: the analyte and internal standard pitavastatin were both analyzed by MS in the ESI, m/z was 480.0 for rosuvastatin and 420.0 for the IS, separately.",[Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882531/),,480.0,108922,DB08860,Pitavastatin
,21882531,m/z,"Plasma samples were determined with LC-MS: the analyte and internal standard pitavastatin were both analyzed by MS in the ESI, m/z was 480.0 for rosuvastatin and 420.0 for the IS, separately.",[Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882531/),,420.0,108923,DB08860,Pitavastatin
,28159531,flow rate,"Waters XTerra RP HPLC column (4.6×100mm, 5μm) with mobile phase consisting of acetonitrile and 10mM ammonium acetate (pH-6.0) in the ratio 85:15 (v/v) at a flow rate of 1mL/min was used for the chromatographic separation.",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),[ml] / [min],1,113708,DB08860,Pitavastatin
,28159531,m/,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,420.17,113709,DB08860,Pitavastatin
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,489.59,113710,DB08860,Pitavastatin
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,350.12,113711,DB08860,Pitavastatin
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,380.08,113712,DB08860,Pitavastatin
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,316.31,113713,DB08860,Pitavastatin
,28159531,total run time,A total run time of 3min and LLOQ was found to be 5ng/mL for both PIT and GLI.,A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),min,3,113714,DB08860,Pitavastatin
,28159531,total run time,A total run time of 3min and LLOQ was found to be 5ng/mL for both PIT and GLI.,A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),[ng] / [ml],5,113715,DB08860,Pitavastatin
,17703482,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 423 --> 101, 420 --> 290 and 410 --> 348 for pravastatin, pitavastatin and fluvastatin, respectively.","Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703482/),,423,114040,DB08860,Pitavastatin
,17703482,limit of detection,The limit of detection was 1 ng/mL for all analytes.,"Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703482/),[ng] / [ml],1,114041,DB08860,Pitavastatin
,25202920,area under the concentration time curve (AUC0-τ),"In the EFV arm, the geometric mean area under the concentration time curve (AUC0-τ) and Cmax of pitavastatin were 85.3 ng·h·mL and 15.6 ng/mL, respectively, when given alone, versus 76 ng·h·mL and 18.8 ng/mL when coadministered with EFV.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),h·ml·ng,85.3,117705,DB08860,Pitavastatin
,25202920,area under the concentration time curve (AUC0-τ),"In the EFV arm, the geometric mean area under the concentration time curve (AUC0-τ) and Cmax of pitavastatin were 85.3 ng·h·mL and 15.6 ng/mL, respectively, when given alone, versus 76 ng·h·mL and 18.8 ng/mL when coadministered with EFV.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),h·ml·ng,76,117706,DB08860,Pitavastatin
,25202920,Cmax,"In the EFV arm, the geometric mean area under the concentration time curve (AUC0-τ) and Cmax of pitavastatin were 85.3 ng·h·mL and 15.6 ng/mL, respectively, when given alone, versus 76 ng·h·mL and 18.8 ng/mL when coadministered with EFV.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),[ng] / [ml],15.6,117707,DB08860,Pitavastatin
,25202920,Cmax,"In the EFV arm, the geometric mean area under the concentration time curve (AUC0-τ) and Cmax of pitavastatin were 85.3 ng·h·mL and 15.6 ng/mL, respectively, when given alone, versus 76 ng·h·mL and 18.8 ng/mL when coadministered with EFV.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),[ng] / [ml],18.8,117708,DB08860,Pitavastatin
,25202920,AUC0-τ,"In the DRV/r arm, AUC0-τ and Cmax were 62.8 ng·h·mL and 24.0 ng/mL, respectively, when pitavastatin was administered alone, versus 56.9 ng·h·mL and 23.2 ng/mL when coadministered with DRV/r.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),h·ml·ng,62.8,117709,DB08860,Pitavastatin
,25202920,AUC0-τ,"In the DRV/r arm, AUC0-τ and Cmax were 62.8 ng·h·mL and 24.0 ng/mL, respectively, when pitavastatin was administered alone, versus 56.9 ng·h·mL and 23.2 ng/mL when coadministered with DRV/r.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),h·ml·ng,56.9,117710,DB08860,Pitavastatin
,25202920,Cmax,"In the DRV/r arm, AUC0-τ and Cmax were 62.8 ng·h·mL and 24.0 ng/mL, respectively, when pitavastatin was administered alone, versus 56.9 ng·h·mL and 23.2 ng/mL when coadministered with DRV/r.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),[ng] / [ml],24.0,117711,DB08860,Pitavastatin
,25202920,Cmax,"In the DRV/r arm, AUC0-τ and Cmax were 62.8 ng·h·mL and 24.0 ng/mL, respectively, when pitavastatin was administered alone, versus 56.9 ng·h·mL and 23.2 ng/mL when coadministered with DRV/r.",Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25202920/),[ng] / [ml],23.2,117712,DB08860,Pitavastatin
,15752374,Cmax,"The geomean Cmax of pitavastatin was 59.5 ng ml(-1), 70.7 ng ml(-1) and 147.1 ng ml(-1) in the control, Child-Pugh grade A and Child-Pugh grade B groups, respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [ml],59.5,118044,DB08860,Pitavastatin
,15752374,Cmax,"The geomean Cmax of pitavastatin was 59.5 ng ml(-1), 70.7 ng ml(-1) and 147.1 ng ml(-1) in the control, Child-Pugh grade A and Child-Pugh grade B groups, respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [ml],70.7,118045,DB08860,Pitavastatin
,15752374,Cmax,"The geomean Cmax of pitavastatin was 59.5 ng ml(-1), 70.7 ng ml(-1) and 147.1 ng ml(-1) in the control, Child-Pugh grade A and Child-Pugh grade B groups, respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [ml],147.1,118046,DB08860,Pitavastatin
,15752374,AUCt,"The geomean AUCt of pitavastatin in the three groups was 121.2 ng h(-1) ml(-1), 154.2 ng h(-1) ml(-1) and 441.7 ng h(-1) ml(-1), respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [h·ml],121.2,118047,DB08860,Pitavastatin
,15752374,AUCt,"The geomean AUCt of pitavastatin in the three groups was 121.2 ng h(-1) ml(-1), 154.2 ng h(-1) ml(-1) and 441.7 ng h(-1) ml(-1), respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [h·ml],154.2,118048,DB08860,Pitavastatin
,15752374,AUCt,"The geomean AUCt of pitavastatin in the three groups was 121.2 ng h(-1) ml(-1), 154.2 ng h(-1) ml(-1) and 441.7 ng h(-1) ml(-1), respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [h·ml],441.7,118049,DB08860,Pitavastatin
,15752374,Cmax,"The geomean Cmax of pitavastatin lactone was 20.3 ng ml(-1), 19.1 ng ml(-1) and 9.9 ng ml(-1) in the control, Child-Pugh grade A and grade B groups, respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [ml],20.3,118050,DB08860,Pitavastatin
,15752374,Cmax,"The geomean Cmax of pitavastatin lactone was 20.3 ng ml(-1), 19.1 ng ml(-1) and 9.9 ng ml(-1) in the control, Child-Pugh grade A and grade B groups, respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [ml],19.1,118051,DB08860,Pitavastatin
,15752374,Cmax,"The geomean Cmax of pitavastatin lactone was 20.3 ng ml(-1), 19.1 ng ml(-1) and 9.9 ng ml(-1) in the control, Child-Pugh grade A and grade B groups, respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),[ng] / [ml],9.9,118052,DB08860,Pitavastatin
,15752374,AUCt,"The AUCt of pitavastatin lactone was 120.2 h(-1) ml(-1), 108.8 h(-1) ml(-1) and 87.5 h(-1) ml(-1), respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),1/[h·ml],120.2,118053,DB08860,Pitavastatin
,15752374,AUCt,"The AUCt of pitavastatin lactone was 120.2 h(-1) ml(-1), 108.8 h(-1) ml(-1) and 87.5 h(-1) ml(-1), respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),1/[h·ml],108.8,118054,DB08860,Pitavastatin
,15752374,AUCt,"The AUCt of pitavastatin lactone was 120.2 h(-1) ml(-1), 108.8 h(-1) ml(-1) and 87.5 h(-1) ml(-1), respectively.",Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752374/),1/[h·ml],87.5,118055,DB08860,Pitavastatin
,23007012,AUC(last),"Pitavastatin AUC(last) was higher in individuals carrying the SLCO1B1*15 allele than those not carrying it (144.1 ± 55.3 vs. 84.7 ± 25.7 h·ng/mL [mean ± SD], p = 0.002).","Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007012/),[h·ng] / [ml],144.1,146377,DB08860,Pitavastatin
,23007012,AUC(last),"Pitavastatin AUC(last) was higher in individuals carrying the SLCO1B1*15 allele than those not carrying it (144.1 ± 55.3 vs. 84.7 ± 25.7 h·ng/mL [mean ± SD], p = 0.002).","Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007012/),[h·ng] / [ml],84.7,146378,DB08860,Pitavastatin
,23007012,AUC(last),"The AUC(last) varied significantly according to the ABCC2 C-24T allele (103.4 ± 42.2, 80.2 ± 23.8, and 39.0 h·ng/mL in CC, CT and TT, respectively; p = 0.027).","Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007012/),[h·ng] / [ml],103.4,146379,DB08860,Pitavastatin
,23007012,AUC(last),"The AUC(last) varied significantly according to the ABCC2 C-24T allele (103.4 ± 42.2, 80.2 ± 23.8, and 39.0 h·ng/mL in CC, CT and TT, respectively; p = 0.027).","Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007012/),[h·ng] / [ml],80.2,146380,DB08860,Pitavastatin
,23007012,AUC(last),"The AUC(last) varied significantly according to the ABCC2 C-24T allele (103.4 ± 42.2, 80.2 ± 23.8, and 39.0 h·ng/mL in CC, CT and TT, respectively; p = 0.027).","Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007012/),[h·ng] / [ml],39.0,146381,DB08860,Pitavastatin
,23146221,cumulative urinary excretion percentages,"After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.",Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146221/),%,0.41,157409,DB08860,Pitavastatin
,23146221,cumulative urinary excretion percentages,"After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.",Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23146221/),%,6.1,157410,DB08860,Pitavastatin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,0.06,168541,DB08860,Pitavastatin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,0.66,168542,DB08860,Pitavastatin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,2.57,168543,DB08860,Pitavastatin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,7.79,168544,DB08860,Pitavastatin
≤,28396527,IC50,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,1.7,168545,DB08860,Pitavastatin
,20175818,concentration (C(max)),"The concentration (C(max)) value was higher in the 388GA + 388GG group than that in the 388AA group (39.22 +/- 8.45 vs. 22.90 +/- 4.03 ng/mL, P = 0.006).",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[ng] / [ml],39.22,177598,DB08860,Pitavastatin
,20175818,concentration (C(max)),"The concentration (C(max)) value was higher in the 388GA + 388GG group than that in the 388AA group (39.22 +/- 8.45 vs. 22.90 +/- 4.03 ng/mL, P = 0.006).",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[ng] / [ml],22.90,177599,DB08860,Pitavastatin
,20175818,area under the curve to the last measurable concentration (AUC(0-48)),"The area under the curve to the last measurable concentration (AUC(0-48)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of pitavastatin were lower in the 388AA group than in the 388GA + 388GG group (100.42 +/- 21.19 vs. 182.19 +/- 86.46 ng h/mL, P = 0.024; 108.12 +/- 24.94 vs. 199.64 +/- 98.70 ng h/mL, P = 0.026) respectively.",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[h·ng] / [ml],100.42,177600,DB08860,Pitavastatin
,20175818,area under the curve to the last measurable concentration (AUC(0-48)),"The area under the curve to the last measurable concentration (AUC(0-48)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of pitavastatin were lower in the 388AA group than in the 388GA + 388GG group (100.42 +/- 21.19 vs. 182.19 +/- 86.46 ng h/mL, P = 0.024; 108.12 +/- 24.94 vs. 199.64 +/- 98.70 ng h/mL, P = 0.026) respectively.",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[h·ng] / [ml],182.19,177601,DB08860,Pitavastatin
,20175818,area under the curve extrapolated to infinity (AUC(0-infinity)),"The area under the curve to the last measurable concentration (AUC(0-48)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of pitavastatin were lower in the 388AA group than in the 388GA + 388GG group (100.42 +/- 21.19 vs. 182.19 +/- 86.46 ng h/mL, P = 0.024; 108.12 +/- 24.94 vs. 199.64 +/- 98.70 ng h/mL, P = 0.026) respectively.",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[h·ng] / [ml],182.19,177602,DB08860,Pitavastatin
,20175818,area under the curve extrapolated to infinity (AUC(0-infinity)),"The area under the curve to the last measurable concentration (AUC(0-48)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of pitavastatin were lower in the 388AA group than in the 388GA + 388GG group (100.42 +/- 21.19 vs. 182.19 +/- 86.46 ng h/mL, P = 0.024; 108.12 +/- 24.94 vs. 199.64 +/- 98.70 ng h/mL, P = 0.026) respectively.",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[h·ng] / [ml],108.12,177603,DB08860,Pitavastatin
,20175818,area under the curve extrapolated to infinity (AUC(0-infinity)),"The area under the curve to the last measurable concentration (AUC(0-48)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of pitavastatin were lower in the 388AA group than in the 388GA + 388GG group (100.42 +/- 21.19 vs. 182.19 +/- 86.46 ng h/mL, P = 0.024; 108.12 +/- 24.94 vs. 199.64 +/- 98.70 ng h/mL, P = 0.026) respectively.",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),[h·ng] / [ml],199.64,177604,DB08860,Pitavastatin
,20175818,oral clearance (Cl/F),"The oral clearance (Cl/F) was lower in the 388GA + 388GG group than that in the 388AA group (12.46 +/- 4.79 vs. 19.21 +/- 3.74/h, P = 0.012).",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),1/[h],12.46,177605,DB08860,Pitavastatin
,20175818,oral clearance (Cl/F),"The oral clearance (Cl/F) was lower in the 388GA + 388GG group than that in the 388AA group (12.46 +/- 4.79 vs. 19.21 +/- 3.74/h, P = 0.012).",OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175818/),1/[h],19.21,177606,DB08860,Pitavastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,35,184743,DB08860,Pitavastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,23,184744,DB08860,Pitavastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,31,184745,DB08860,Pitavastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184746,DB08860,Pitavastatin
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],0.943,184747,DB08860,Pitavastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184748,DB08860,Pitavastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,16,184749,DB08860,Pitavastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],3.39,184750,DB08860,Pitavastatin
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],5.48,184751,DB08860,Pitavastatin
,34329714,half-lives,"The half-lives of ginkgolides A, B, C, and bilobalide (2-3 h) were shorter than quercetin, kaempferol, and isorhamnetin (approximately 20 h).","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),h,2-3,186315,DB08860,Pitavastatin
,34329714,half-lives,"The half-lives of ginkgolides A, B, C, and bilobalide (2-3 h) were shorter than quercetin, kaempferol, and isorhamnetin (approximately 20 h).","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),h,20,186316,DB08860,Pitavastatin
,34329714,IC50,"In hOATP1B1-HEK293 cells, kaempferol and isorhamnetin contributed to the inhibition of OATP1B1-mediated uptake of 3H-ES with IC50 values of 3.28 ± 1.08 μM and 46.12 ± 5.25 μM, respectively.","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),μM,3.28,186317,DB08860,Pitavastatin
,34329714,IC50,"In hOATP1B1-HEK293 cells, kaempferol and isorhamnetin contributed to the inhibition of OATP1B1-mediated uptake of 3H-ES with IC50 values of 3.28 ± 1.08 μM and 46.12 ± 5.25 μM, respectively.","Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329714/),μM,46.12,186318,DB08860,Pitavastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB08860,Pitavastatin
,22627182,area under the concentration time curve (AUC0-τ),"For pitavastatin, area under the concentration time curve (AUC0-τ) and maximum concentration (C(max)) were 136.8 ± 52.9 ng·h(-1)·mL(-1) and 58.6 ± 30.4 ng/mL, respectively, when given alone, versus 113.9 ± 53.8 ng·h(-1)·mL(-1) and 58.2 ± 32.7 ng/mL when combined with lopinavir/ritonavir.",Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22627182/),[ng] / [h·ml],136.8,188800,DB08860,Pitavastatin
,22627182,area under the concentration time curve (AUC0-τ),"For pitavastatin, area under the concentration time curve (AUC0-τ) and maximum concentration (C(max)) were 136.8 ± 52.9 ng·h(-1)·mL(-1) and 58.6 ± 30.4 ng/mL, respectively, when given alone, versus 113.9 ± 53.8 ng·h(-1)·mL(-1) and 58.2 ± 32.7 ng/mL when combined with lopinavir/ritonavir.",Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22627182/),[ng] / [h·ml],113.9,188801,DB08860,Pitavastatin
,22627182,maximum concentration (C(max)),"For pitavastatin, area under the concentration time curve (AUC0-τ) and maximum concentration (C(max)) were 136.8 ± 52.9 ng·h(-1)·mL(-1) and 58.6 ± 30.4 ng/mL, respectively, when given alone, versus 113.9 ± 53.8 ng·h(-1)·mL(-1) and 58.2 ± 32.7 ng/mL when combined with lopinavir/ritonavir.",Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22627182/),[ng] / [ml],58.6,188802,DB08860,Pitavastatin
,22627182,maximum concentration (C(max)),"For pitavastatin, area under the concentration time curve (AUC0-τ) and maximum concentration (C(max)) were 136.8 ± 52.9 ng·h(-1)·mL(-1) and 58.6 ± 30.4 ng/mL, respectively, when given alone, versus 113.9 ± 53.8 ng·h(-1)·mL(-1) and 58.2 ± 32.7 ng/mL when combined with lopinavir/ritonavir.",Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22627182/),[ng] / [ml],58.2,188803,DB08860,Pitavastatin
,22627182,T(max),Median T(max) of pitavastatin was approximately 0.5 hours for both treatments.,Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22627182/),h,0.5,188804,DB08860,Pitavastatin
,21069099,area under the plasma concentration-time curve,"The mean values for the area under the plasma concentration-time curve for atorvastatin and ortho-hydroxy atorvastatin were 63.1 and 46.9 ng.h/mL, respectively.",Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069099/),[h·ng] / [ml],63.1,203685,DB08860,Pitavastatin
,21069099,area under the plasma concentration-time curve,"The mean values for the area under the plasma concentration-time curve for atorvastatin and ortho-hydroxy atorvastatin were 63.1 and 46.9 ng.h/mL, respectively.",Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069099/),[h·ng] / [ml],46.9,203686,DB08860,Pitavastatin
,22077103,AUC(inf),"However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin.",Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077103/),[h·ng] / [ml],285.5,207693,DB08860,Pitavastatin
,22077103,AUC(inf),"However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin.",Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077103/),[h·ng] / [ml],164.6,207694,DB08860,Pitavastatin
,22077103,C(max),"However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin.",Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077103/),[ng] / [ml],106.7,207695,DB08860,Pitavastatin
,22077103,C(max),"However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin.",Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077103/),[ng] / [ml],48.3,207696,DB08860,Pitavastatin
,22077103,apparent oral clearance,"However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin.",Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077103/),[l] / [h],13.1,207697,DB08860,Pitavastatin
,22077103,apparent oral clearance,"However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin.",Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22077103/),[l] / [h],6.9,207698,DB08860,Pitavastatin
,25138679,maximum plasma concentration (C(max)),"In the UDCA phase, the maximum plasma concentration (C(max)) of pitavastatin was slightly higher than in the control phase (48.6 ± 22.9 ng/mL vs. 42.4 ± 16.1 ng/mL).","Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138679/),[ng] / [ml],48.6,222161,DB08860,Pitavastatin
,25138679,maximum plasma concentration (C(max)),"In the UDCA phase, the maximum plasma concentration (C(max)) of pitavastatin was slightly higher than in the control phase (48.6 ± 22.9 ng/mL vs. 42.4 ± 16.1 ng/mL).","Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138679/),[ng] / [ml],42.4,222162,DB08860,Pitavastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,80,226815,DB08860,Pitavastatin
,12616706,bioavailability,"Pitavastatin is the exception, with high bioavailability in all species except monkeys (80% vs. 18%).",Preclinical pharmacokinetics of statins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,18,226816,DB08860,Pitavastatin
>,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,95,226817,DB08860,Pitavastatin
,12616706,Plasma protein binding,Plasma protein binding is high for all statins (> 95%) except pravastatin (60%).,Preclinical pharmacokinetics of statins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616706/),%,60,226818,DB08860,Pitavastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB08860,Pitavastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB08860,Pitavastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB08860,Pitavastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB08860,Pitavastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB08860,Pitavastatin
,16198653,AUCs,"Dose-normalized pitavastatin AUCs for *1b/*1b (group 1), *1a/*1a or *1a/*1b (group 2), and *1a/*15 or *1b/*15 (group 3) were 38.8+/-13.3, 54.4 +/-12.4, and 68.1+/-6.3 ng.h.mL(-1).",Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198653/),[h·ng] / [ml],38.8,247263,DB08860,Pitavastatin
,16198653,AUCs,"Dose-normalized pitavastatin AUCs for *1b/*1b (group 1), *1a/*1a or *1a/*1b (group 2), and *1a/*15 or *1b/*15 (group 3) were 38.8+/-13.3, 54.4 +/-12.4, and 68.1+/-6.3 ng.h.mL(-1).",Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198653/),[h·ng] / [ml],54.4,247264,DB08860,Pitavastatin
,16198653,AUCs,"Dose-normalized pitavastatin AUCs for *1b/*1b (group 1), *1a/*1a or *1a/*1b (group 2), and *1a/*15 or *1b/*15 (group 3) were 38.8+/-13.3, 54.4 +/-12.4, and 68.1+/-6.3 ng.h.mL(-1).",Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198653/),[h·ng] / [ml],68.1,247265,DB08860,Pitavastatin
,16198653,C(max),"Dose-normalized pitavastatin C(max) values were 13.2+/- 3.3, 18.2+/-5.7, and 29.4+/- 9.6 ng.",Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198653/),ng,13.2,247266,DB08860,Pitavastatin
,16198653,C(max),"Dose-normalized pitavastatin C(max) values were 13.2+/- 3.3, 18.2+/-5.7, and 29.4+/- 9.6 ng.",Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198653/),ng,18.2,247267,DB08860,Pitavastatin
,16198653,C(max),"Dose-normalized pitavastatin C(max) values were 13.2+/- 3.3, 18.2+/-5.7, and 29.4+/- 9.6 ng.",Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198653/),ng,29.4,247268,DB08860,Pitavastatin
,19398603,area,"Furthermore, the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0 to 10 hours showed no significant differences among 3 statins (simvastatin: 0.32 +/- 0.09, atorvastatin: 0.31 +/- 0.09, and pitavastatin: 0.31 +/- 0.12).",Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398603/),,0,249583,DB08860,Pitavastatin
,27643859,flow rate,"The samples were chromatographed on an Inertsil ODS-3 C18 column (100mm×2.1mm, 2μm) using a mixture of acetonitrile and 10mM ammonium acetate containing 0.1% formic acid (60: 40, v/v) as the mobile phase at a flow rate of 0.4mL/min.",Simultaneous determination of telmisartan and pitavastatin in rat plasma by UPLC-MS/MS: Application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27643859/),[ml] / [min],0.4,253138,DB08860,Pitavastatin
,18716369,vascular peroxynitrite,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254078,DB08860,Pitavastatin
,18716369,concentration,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254079,DB08860,Pitavastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],1.44,256262,DB08860,Pitavastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],30.6,256263,DB08860,Pitavastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],12.7,256264,DB08860,Pitavastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],62.9,256265,DB08860,Pitavastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],0.84-1.2,256266,DB08860,Pitavastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],14-35,256267,DB08860,Pitavastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],11-19,256268,DB08860,Pitavastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],123-185,256269,DB08860,Pitavastatin
,26082816,Tmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.63,274053,DB08860,Pitavastatin
,26082816,Tmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.65,274054,DB08860,Pitavastatin
,26082816,Tmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.79,274055,DB08860,Pitavastatin
,26082816,Cmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],66.80,274056,DB08860,Pitavastatin
,26082816,Cmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],106.09,274057,DB08860,Pitavastatin
,26082816,Cmax,"Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],232.91,274058,DB08860,Pitavastatin
,26082816,AUC0-36,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],190.04,274059,DB08860,Pitavastatin
,26082816,AUC0-36,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],307.87,274060,DB08860,Pitavastatin
,26082816,AUC0-36,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],785.10,274061,DB08860,Pitavastatin
,26082816,t1/2,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,10.99,274062,DB08860,Pitavastatin
,26082816,t1/2,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,9.52,274063,DB08860,Pitavastatin
,26082816,t1/2,"AUC0-36 values were 190.04 (38.97) ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70) hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,10.38,274064,DB08860,Pitavastatin
,26082816,Tmax,"In the multiple-dose study, a rapid absorption (Tmax of 0.68 [0.20] hours) and marked peak concentration of 90.99 (36.88) ng/mL were observed.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,0.68,274065,DB08860,Pitavastatin
,26082816,peak concentration,"In the multiple-dose study, a rapid absorption (Tmax of 0.68 [0.20] hours) and marked peak concentration of 90.99 (36.88) ng/mL were observed.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [ml],90.99,274066,DB08860,Pitavastatin
,26082816,AUC0-48,"AUC0-48 and AUCss were 306.28 (130.02) ng/mL/h and 256.16 (116.34) ng/mL/h, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],306.28,274067,DB08860,Pitavastatin
,26082816,AUCss,"AUC0-48 and AUCss were 306.28 (130.02) ng/mL/h and 256.16 (116.34) ng/mL/h, respectively.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),[ng] / [h·ml],256.16,274068,DB08860,Pitavastatin
,26082816,elimination half-life,"The elimination half-life after multiple dosing was significantly prolonged, which amounted to 13.31 (2.58) hours.",Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082816/),h,13.31,274069,DB08860,Pitavastatin
